| Entry |
|
|---|
| Name |
Gemcitabine hydrochloride (JAN/USP);
Gemzar (TN) |
|---|
| Product |
|
|---|
| Generic |
GEMCITABINE (Armas Pharmaceuticals), GEMCITABINE (Armas Pharmaceuticals), GEMCITABINE (Armas Pharmaceuticals), GEMCITABINE (Dr. Reddy's Laboratories Limited), GEMCITABINE (Fresenius Kabi USA), GEMCITABINE (Fresenius Kabi USA), GEMCITABINE (Fresenius Kabi USA), GEMCITABINE (Hikma Pharmaceuticals USA), GEMCITABINE (Hospira), GEMCITABINE (Hospira), GEMCITABINE (Ingenus Pharmaceuticals), GEMCITABINE (Meitheal Pharmaceuticals), GEMCITABINE (Meitheal Pharmaceuticals), GEMCITABINE (Mylan Institutional LLC), GEMCITABINE (NorthStar Rx LLC), GEMCITABINE (Sagent Pharmaceuticals), GEMCITABINE HYDROCHLORIDE (Gland Pharma Limited), GEMCITABINE HYDROCHLORIDE (Teyro Labs Private Limited) |
|---|
| Formula |
C9H11F2N3O4. HCl
|
|---|
| Exact mass |
299.0484
|
|---|
| Mol weight |
299.66
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
|
|---|
| Remark |
| Therapeutic category: | 4224 |
| Product (DG00688): | D01155<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Antimetabolite |
|---|
| Disease |
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07041 | Antineoplastics - antimetabolic agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01B ANTIMETABOLITES
L01BC Pyrimidine analogues
L01BC05 Gemcitabine
D01155 Gemcitabine hydrochloride (JAN/USP) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antimetabolites
Gemcitabine
D01155 Gemcitabine hydrochloride (JAN/USP)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
422 Antimetabolites
4224 Cytosines
D01155 Gemcitabine hydrochloride (JAN/USP)
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG00688 Gemcitabine
D01155 Gemcitabine hydrochloride
Drug classes [BR:br08332]
Antineoplastic
DG02018 Antimetabolite
D01155 Gemcitabine hydrochloride
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Ribonucleoside-diphosphate reductase
RRM1
D01155 Gemcitabine hydrochloride (JAN/USP) <JP/US>
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG00688 Gemcitabine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 19
1 X Cl 23.2764 -19.8780
2 C1y C 17.7120 -17.4316
3 N4y N 19.0399 -16.3826
4 C1z C 17.3620 -18.7617
5 O2x O 16.5919 -16.5915
6 C8y C 20.2923 -17.0271
7 C8x C 19.0366 -15.0038
8 C1y C 15.8918 -18.7617
9 X F 17.3620 -20.1618
10 X F 18.6221 -18.7617
11 C1y C 15.4718 -17.4316
12 N5x N 21.4481 -16.2155
13 O5x O 20.2882 -18.2891
14 C8x C 20.2624 -14.1922
15 O1a O 15.0518 -19.8118
16 C1b C 14.2817 -17.0116
17 C8y C 21.4448 -14.8367
18 O1a O 13.2316 -18.0616
19 N1a N 22.6122 -14.0638
BOND 19
1 2 3 1 #Up
2 2 4 1
3 2 5 1
4 3 6 1
5 3 7 1
6 4 8 1
7 4 9 1
8 4 10 1
9 5 11 1
10 6 12 1
11 6 13 2
12 7 14 2
13 8 15 1 #Down
14 11 16 1 #Up
15 12 17 2
16 16 18 1
17 17 19 1
18 8 11 1
19 14 17 1
|
|---|
